Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed ovarian carcinoma * Recurrent disease * Known platinum-sensitive recurrent disease after no more than 2 prior salvage regimens * Measurable disease as defined by a target lesion and a CA125 level * No epithelial ovarian carcinoma of low malignant potential PATIENT CHARACTERISTICS: Inclusion criteria: * GOG performance status 0, 1, or 2 * Life expectancy \> 6 months * Absolute neutrophil count ≥ 1,500/uL * Platelet count ≥ 100,000/uL * Hemoglobin \> 9.0 g/dL * Creatinine ≤ 2.0 mg/dL * Bilirubin ≤ 1.5 x upper limit of normal (ULN) * SGOT and alkaline phosphatase ≤ 3 x ULN * Neuropathy (sensory and motor) ≤ CTCAE grade 1 Exclusion criteria: * GOG performance status 3 or 4 * Pregnant or breastfeeding * History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of DOXIL® * Abnormal LVEF as determined by gated cardiac radionucleotide scan (MUGA) * Septicemia or severe infection * Acute hepatitis or severe gastrointestinal bleeding * Any of the following: * Unstable angina * Myocardial infarction within the past 6 months * NYHA class II-IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * Clinically significant pericardial disease * Electrocardiographic evidence of acute ischemic or active conduction system abnormalities * Patients with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible if their disease has been stable for the past six months * Other invasive malignancies within the past 5 years except for nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Inclusion criteria: * See Disease Characteristics * At least 6 months since prior adjuvant regimen * At least 4 weeks since prior salvage treatment * May have received secondary cytoreduction for recurrent ovarian cancer * May have received prior intraperitoneal therapy for ovarian cancer * May have received no more than 2 prior platinum and taxane-based regimens * May have received prior intraperitoneal platinum during front-line treatment Exclusion criteria: * Prior anthracycline dose exceeding 360 mg/m\^2 for doxorubicin hydrochloride (including DOXIL®) or 720 mg/m\^2 for epirubicin hydrochloride * Prior radiotherapy * Prior intraperitoneal carboplatin or cisplatin as salvage treatment for recurrent ovarian cancer * Concurrent amifostine or other protective agents